# Parabilis Medicines

> Parabilis Medicines is a clinical-stage biopharmaceutical company in Cambridge, Massachusetts building stabilized, cell-penetrant alpha-helical peptides - called Helicons - that reach intracellular and 'undruggable' protein targets out of range for traditional small molecules and biologics. Formerly FogPharma, the company's lead candidate zolucatetide (FOG-001) is the first direct inhibitor of the beta-catenin/TCF interaction driving Wnt-pathway cancers, and is heading toward a registrational Phase 3 trial in desmoid tumors. Led by CEO Mathai Mammen and founded on Gregory Verdine's stapled-peptide chemistry, Parabilis has raised more than $860M, signed an up-to-$2.3B collaboration with Regeneron, and filed to go public on Nasdaq under the ticker PBLS.

- **Founded:** 2015
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Gregory L. Verdine (Founder, inventor of stapled-peptide / Helicon chemistry), Mathai Mammen (Chairman & CEO)
- **Team size:** ~170 employees
- **Products:** Helicon Platform, Zolucatetide (FOG-001), Antibody-Helicon Conjugates
- **Notable:** Pioneered Helicon stabilized alpha-helical peptide platform built on Gregory Verdine's 2000 stapled-peptide discovery, Advanced zolucatetide (FOG-001) to Phase 3-ready status as the first direct beta-catenin/TCF inhibitor, Reported 100% (25/25) tumor reductions among evaluable desmoid tumor patients and 74% objective response among those with two post-baseline scans

## Products & services

- **Helicon Platform** — A discovery engine combining AI- and physics-based design with 26 years of peptide chemistry to produce stabilized, cell-penetrant alpha-helical peptides that engage intracellular targets and flat protein surfaces unsuited to small molecules.
- **Zolucatetide (FOG-001)** — Lead clinical candidate; the first direct inhibitor of the beta-catenin/TCF transcription-factor interaction, targeting Wnt/beta-catenin-driven solid tumors including desmoid tumors, colorectal cancer, hepatocellular carcinoma and rarer cancers like ameloblastoma and craniopharyngioma.
- **Antibody-Helicon Conjugates** — Next-generation modality (with Regeneron) that links antibodies to Helicon peptides for targeted intracellular delivery across multiple therapeutic areas.

## Achievements

- Pioneered Helicon stabilized alpha-helical peptide platform built on Gregory Verdine's 2000 stapled-peptide discovery
- Advanced zolucatetide (FOG-001) to Phase 3-ready status as the first direct beta-catenin/TCF inhibitor
- Reported 100% (25/25) tumor reductions among evaluable desmoid tumor patients and 74% objective response among those with two post-baseline scans
- Closed oversubscribed $305M Series F in January 2026
- Signed up-to-$2.3B Regeneron collaboration in May 2026
- Filed for a Nasdaq IPO (PBLS) targeting up to ~$476M

## Latest updates

- **2026-05** — Announced strategic antibody-Helicon conjugate collaboration with Regeneron worth up to ~$2.3B; filed for Nasdaq IPO the following day.
- **2026-01** — Closed oversubscribed $305M Series F to fund FOG-001 (zolucatetide) clinical development and advance the Helicon platform.
- **2025-11** — Presented Helicon clinical and preclinical data at AACR-NCI-EORTC 2025 and craniopharyngioma results at SNO 2025.
- **2024-10** — Rebranded from FogPharma to Parabilis Medicines and unveiled its AI- and physics-based discovery platform.

## Links

- Website: https://parabilismed.com
- LinkedIn: http://www.linkedin.com/company/parabilis-medicines

---

Profile page: https://yespress.io/parabilis-medicines
Published by YesPress — https://yespress.io
Last updated: 2026-06-07